PP
EWTX icon

PDT Partners’s Edgewise Therapeutics EWTX Stock Holding History

PDT Partners’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,551
Closed -$549K – 750
2024
Q3 		$549K Sell
20,551
-5,736
-22% -$114K 0.05% 481
2024
Q2 		$473K Sell
26,287
-72
-0.3% -$1.26K 0.04% 472
2024
Q1 		$481K Sell
26,359
-2,900
-10% -$46.1K 0.05% 463
2023
Q4 		$320K Buy
+29,259
New +$205K 0.04% 454
2023
Q3 		– Sell
-24,935
Closed -$193K – 612
2023
Q2 		$193K Buy
24,935
+5,592
+29% +$47.2K 0.03% 505
2023
Q1 		$129K Buy
19,343
+108
+0.6% +$1K 0.02% 525
2022
Q4 		$172K Sell
19,235
-4,422
-19% -$41.5K 0.03% 554
2022
Q3 		$233K Buy
+23,657
New +$239K 0.04% 669

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

PDT Partners's EWTX Position: Q4 2024 in Review

PDT Partners sold out of Edgewise Therapeutics (EWTX) in Q4 2024, closing a stake of 20,551 shares — an estimated $549K sold.

PDT Partners first reported a position in EWTX in Q3 2022 and held it in 8 quarters. The position peaked at $549K in Q3 2024. 200 funds tracked by Wall St. Rank hold EWTX as of Q4 2024.

  • PDT Partners reported no remaining Edgewise Therapeutics position as of Q4 2024 after selling out during the quarter.
  • PDT Partners sold 20,551 Edgewise Therapeutics shares in Q4 2024, an estimated $549K.
  • PDT Partners first reported a position in Edgewise Therapeutics in Q3 2022 and held it in 8 quarters.
  • PDT Partners's Edgewise Therapeutics position peaked at $549K in Q3 2024.
  • 200 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2024.

Based on PDT Partners's 13F filing for Q4 2024, filed 14 Feb 2025.